<DOC>
	<DOCNO>NCT00608140</DOCNO>
	<brief_summary>Mitral regurgitation ( MR ) , also know mitral insufficiency , condition heart 's mitral valve , locate two heart 's main chamber , firmly shut , allow blood leak backwards within heart . Improper function mitral valve disrupts proper flow blood body , result shortness breath fatigue . When mild , MR may pose significant danger person 's health , severe MR may associate serious complication , heart failure , irregular heart rhythm , high blood pressure . Although treatment MR , include medication surgery , information need effectiveness treatment people significant MR . This study compare safety effectiveness corrective surgery add optimal medical treatment ( OMT ) versus OMT alone treat people significant MR cause enlarged heart .</brief_summary>
	<brief_title>Effectiveness Surgical Mitral Valve Repair Versus Medical Treatment People With Significant Mitral Regurgitation Non-ischemic Congestive Heart Failure</brief_title>
	<detailed_description>It estimate approximately 4 10 people enlarged heart due heart failure develop MR , refer secondary MR . This type MR cause enlargement left ventricle ( LV ) , one heart 's main chamber . In turn , enlargement lead stretch certain heart muscle around mitral valve valve . Symptoms secondary MR may include shortness breath , fatigue , dizziness , swollen foot , cough , heart palpitation . Mitral valve repair replacement surgery sometimes consider treatment option restore proper heart function people secondary MR. Surgical repair placement artificial ring around mitral valve help tighten valve add benefit non-surgical treatment MR . However , although surgical placement ring improves mitral valve function people , know whether surgery help people live long healthy life . This study compare safety effectiveness surgical mitral valvuloplasty placement annular ring ( SMVR ) add optimal medical treatment ( OMT ) versus OMT alone non-ischemic heart failure patient significant secondary MR . Participation baseline follow-up study last 18 month . All potential participant initially undergo transesophageal echocardiogram confirm presence abnormal mitral valve . Eligible participant undergo number baseline test , include cardiopulmonary exercise stress testing , chest wall echocardiogram , blood draw , 6-minute walk test , medical questionnaire , physical exam . Next , participant randomly assign receive immediate open heart surgery placement mitral valve ring , delay surgery least 18 month later , OMT . Participants assign receive immediate surgery undergo surgery 2 week baseline test . Participants assign receive OMT receive treatment follow medication regimen : combination vasodilator therapy diuretic , nitrate nifedipine , beta-adrenergic blocker therapy . Follow-up visit participant occur Months 1 , 3 , 6 , 12 , 18 include repeat baseline testing . Long-term survival status data may collect beyond 18 month participant .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Symptomatic chronic heart failure , New York Heart Association ( NYHA ) class II IIIb Left ventricular ejection fraction 0.35 due nonischemic etiology Evidence transthoracic echocardiography ( TTE ) moderate severe MR without obvious primary mitral valve pathology Peak VO2 less equal 22 ml/kg/min , obtain study entry Optimal heart failure therapy least 6 month prior study entry Significant coronary artery disease ( great 75 % lesion vessel ) coronary angiography history prior heart attack Heart failure due active myocarditis , congenital heart disease , obstructive hypertrophic cardiomyopathy Significant ventricular arrhythmia treat implantable defibrillator Primary MR due significant chordal leaflet abnormality TTE Other hemodynamically relevant stenotic regurgitant valvular disease Severe tricuspid regurgitation ( TR ) ( moderate TR allow ) Severe pulmonic regurgitation ( PR ) ( moderate PR allow ) Moderate severe aortic regurgitation Any moderate severe stenotic lesion use American Heart Association/American College Cardiology ( AHA/ACC ) criteria 31 Dependence chronic inotropic therapy Restrictive cardiomyopathy constrictive pericarditis Severe right ventricular dysfunction Baseline creatinine great equal 3 mg/dL renal replacement therapy ( chronic hemodialysis peritoneal dialysis ) Poor transthoracic sonographic window preclude reasonable assessment LV endocardial border apical image TTE Inability perform spirometric exercise test Significant chronic lung disease might interfere ability interpret spirometric measurement , include home oxygen , force expiratory volume 1 second ( FEV1 ) less 1.0 L/min , exertional hypoxemia saturation less 90 % Any know neoplastic disease skin cancer Other terminal illness life expectancy le 1 year Plan percutaneous mitral valve procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Advanced Heart Failure</keyword>
	<keyword>Non-Ischemic Heart Failure</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Mitral Valve Replacement</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Surgical Mitral Valvuloplasty</keyword>
	<keyword>Dilated Cardiomyopathy</keyword>
	<keyword>Annular Ring</keyword>
</DOC>